These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 14578343)

  • 1. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.
    Rodriguez M; Yu X; Chen J; Songyang Z
    J Biol Chem; 2003 Dec; 278(52):52914-8. PubMed ID: 14578343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains.
    Botuyan MV; Nominé Y; Yu X; Juranic N; Macura S; Chen J; Mer G
    Structure; 2004 Jul; 12(7):1137-46. PubMed ID: 15242590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BRCT domain is a phospho-protein binding domain.
    Yu X; Chini CC; He M; Mer G; Chen J
    Science; 2003 Oct; 302(5645):639-42. PubMed ID: 14576433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCT repeats as phosphopeptide-binding modules involved in protein targeting.
    Manke IA; Lowery DM; Nguyen A; Yaffe MB
    Science; 2003 Oct; 302(5645):636-9. PubMed ID: 14576432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.
    Shiozaki EN; Gu L; Yan N; Shi Y
    Mol Cell; 2004 May; 14(3):405-12. PubMed ID: 15125843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.
    Varma AK; Brown RS; Birrane G; Ladias JA
    Biochemistry; 2005 Aug; 44(33):10941-6. PubMed ID: 16101277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.
    Clapperton JA; Manke IA; Lowery DM; Ho T; Haire LF; Yaffe MB; Smerdon SJ
    Nat Struct Mol Biol; 2004 Jun; 11(6):512-8. PubMed ID: 15133502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BRCA1 C-terminal domain: structure and function.
    Huyton T; Bates PA; Zhang X; Sternberg MJ; Freemont PS
    Mutat Res; 2000 Aug; 460(3-4):319-32. PubMed ID: 10946236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1.
    Lokesh GL; Rachamallu A; Kumar GD; Natarajan A
    Anal Biochem; 2006 May; 352(1):135-41. PubMed ID: 16500609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDC1 is a mediator of the mammalian DNA damage checkpoint.
    Stewart GS; Wang B; Bignell CR; Taylor AM; Elledge SJ
    Nature; 2003 Feb; 421(6926):961-6. PubMed ID: 12607005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of a second BRCT domain identified in the nijmegen breakage syndrome protein Nbs1 and its function in an MDC1-dependent localization of Nbs1 to DNA damage sites.
    Xu C; Wu L; Cui G; Botuyan MV; Chen J; Mer G
    J Mol Biol; 2008 Aug; 381(2):361-72. PubMed ID: 18582474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for the BRCA1 BRCT interaction with the proteins ATRIP and BAAT1.
    Liu X; Ladias JA
    Biochemistry; 2013 Oct; 52(43):7618-27. PubMed ID: 24073851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the BRCT repeat domain of MDC1 and its specificity for the free COOH-terminal end of the gamma-H2AX histone tail.
    Lee MS; Edwards RA; Thede GL; Glover JN
    J Biol Chem; 2005 Sep; 280(37):32053-6. PubMed ID: 16049003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
    Tischkowitz M; Hamel N; Carvalho MA; Birrane G; Soni A; van Beers EH; Joosse SA; Wong N; Novak D; Quenneville LA; Grist SA; ; Nederlof PM; Goldgar DE; Tavtigian SV; Monteiro AN; Ladias JA; Foulkes WD
    Eur J Hum Genet; 2008 Jul; 16(7):820-32. PubMed ID: 18285836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations.
    Nominé Y; Botuyan MV; Bajzer Z; Owen WG; Caride AJ; Wasielewski E; Mer G
    Biochemistry; 2008 Sep; 47(37):9866-79. PubMed ID: 18717574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphopeptide interactions with BRCA1 BRCT domains: More than just a motif.
    Wu Q; Jubb H; Blundell TL
    Prog Biophys Mol Biol; 2015 Mar; 117(2-3):143-148. PubMed ID: 25701377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.
    Wu W; Togashi Y; Johmura Y; Miyoshi Y; Nobuoka S; Nakanishi M; Ohta T
    Cancer Sci; 2016 Oct; 107(10):1406-1415. PubMed ID: 27399284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFBD1, a novel nuclear protein with signature motifs of FHA and BRCT, and an internal 41-amino acid repeat sequence, is an early participant in DNA damage response.
    Shang YL; Bodero AJ; Chen PL
    J Biol Chem; 2003 Feb; 278(8):6323-9. PubMed ID: 12475977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of the BARD1 BRCT domains.
    Birrane G; Varma AK; Soni A; Ladias JA
    Biochemistry; 2007 Jul; 46(26):7706-12. PubMed ID: 17550235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCT domain interactions in the heterodimeric DNA repair protein XRCC1-DNA ligase III.
    Dulic A; Bates PA; Zhang X; Martin SR; Freemont PS; Lindahl T; Barnes DE
    Biochemistry; 2001 May; 40(20):5906-13. PubMed ID: 11352725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.